Protocol to study the antitumor and metabolic effects of intermittent fasting plus cisplatin and metformin in ovarian cancer PDX models.

Different dietary regimens are being explored as safe, low-cost approaches to enhance cancer therapy. This protocol describes the evaluation of antitumor and metabolic effects of intermittent fasting (IF) combined with cisplatin and metformin in an ovarian cancer patient-derived xenograft (PDX) model. Procedures include IF cycles, drug administration, antitumor activity assessment, drug quantification in plasma and tumors, toxicity evaluation, and immunohistochemical analyses. For complete information on the generation and use of this protocol, please refer to Capellini et al.1.